|Access Pharma (OTC: ACCP.OB): MuGard Launch Expected 1Q10|
|Wednesday, 11 November 2009 09:12|
Access Pharma (OTC: ACCP.OB) provided an update today on the status of the North American commercial launch for its FDA cleared treatment for oral mucositis, MuGard, which is expected to occur during 1Q10 in conjunction with the availability of initial product inventory by its liquid contract manufacturing partner, Accupac. In addition, Access signed an e-Marketing deal with iMedicor (OTC: VMCI.OB) in early October as a cost-efficient and highly targeted means of reaching over 200,000 oncologists in the U.S. market.
The e-Marketing deal and pending domestic MuGard launch is part of the Company’s strategy that includes simultaneous discussions for potential co-promotion agreements with oncology-related bio-pharmaceutical companies and the development of a sales team with experience in the supportive treatment of cancer patients. Access is also working with consultants to finalize third-party reimbursement for MuGard from insurance plans, Medicare, Medicaid, etc.
iMedicor’s ClearLobby is an application within the NaviNet healthcare communications portal that includes a network of more than 700,000 physicians. Doctors, healthcare providers, and support staff included in this network have the ability to access information on new medications and medical devices, in addition to medical / scientific journals, clinical trials, webinars, and continuing education programs. Sponsored products such as MuGard go beyond simply providing information, including the capability to order samples and make specific inquiries about the product at their convenience through 24 / 7 access.
The combination of liquid contract manufacturing (Accupac), e-Marketing (iMedicor) / dedicated oncology sales team, and the pending post-approval marketing data from Europe positions Access to launch MuGard in North America on its own in a highly targeted and cost-efficient manner without giving away a large chunk of sales as part of a licensing agreement. In addition, the pending capital raise is likely to be in the $10-15 million range (40-60% of the $25 million maximum in the recent SEC S-1 filing) to further strengthen the balance sheet, fund the MuGard launch, and ultimately improve the Company’s negotiating position for a potential MuGard co-promotion agreement(s).
European MuGard partner, SpePharm, is currently collecting information from approximately 1,500-2,000 patients as part of a comprehensive set of post-marketing / seeding studies being conducted in the UK, Germany, and Italy. SpePharm anticipates that data from these studies will be made on a rolling basis throughout late 2009 to early 2010 while the commercial launch of MuGard in France and other European countries will continue over the next 12-18 months. According to SpePharm, initial patient and clinician feedback has been very positive for MuGard, which validates interim data released from the UK study that demonstrated no cases of oral mucositis in 140 patients who received MuGard while undergoing treatment for head and neck cancer.
Access is also developing its own strategy for similar post-marketing studies in the U.S., if required, to support the use of MuGard as a preventative measure for oral mucositis arising from chemo / radiation therapy in addition to expanding the scope of use for all types of oral trauma such as canker sores, ulcers, and oral surgery complications.
Check out the ProActive News Room landing page for Access and iMedicor, which includes a compilation of digital media coverage links, report downloads, news feeds, and videos.
The BioMedReports.com FDA Calendar service includes a database with over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results.
Coming soon is a premium service offered in collaboration with Investars YOU for full access to a global database of over 1,000 stocks which are organized and managed within my 22 ProActive HavRx stock indexes. This service will allow investors to create custom portfolios, personalized exchange-traded funds (ETFs), and generate investment ideas based on their personal preferences, beliefs, and opinions through specialized stock indexes that are organized and targeted toward a wide variety of themes.
Disclosure: Long ACCP.OB